For example, in a murine HCC model dual anti–PD-1/VEGFR2 treatment significantly inhibited primary tumor growth and (52) and successfully reprogrammed the TME through increased CD8+ T-cell infiltration and activation, shifting the M1:M2 ratio of TAMs, and reducing Treg and chemokine receptor 2 infiltration in HCC tissue. The gene discussed is CD8A; the disease is hepatocellular carcinoma.